How many times do I have to tell you?

I did a quick search on the Deloitte valuation to see how many times the term "generic" was used....using my fingers to count I ran out of digits so started on my toes...if you didnt get it the first time they certainly made sure you eventually got the message.

However there was one counterargument put forward, tucked away under the heading 4.8.2 Specific risks relating to Cellestis

This risk is mitigated in part by the current requirement that any third party seeking to develop and market a unique or generic product that competed with QFT would need to satisfy applicable regulatory requirements associated with the release of the product. These regulatory requirements are currently relatively strict in numerous countries into which Cellestis presently distributes QFT, most notably in the United States, Australia and Japan.

Well of course we all know that the US is CST biggest market - because CST told us so.

Some Quick Facts about the U.S. TB Market…

Largest single market for QFT....US remains main driver of sales and growth

One gripe I have with the IEV is that they appear to spend a lot of time accentuating the negatives whilst virtually eliminating the positives. I guess that is the nature of their business, always looking at the downside.